nodes	percent_of_prediction	percent_of_DWPC	metapath
Droxidopa—Methyldopa—COMT—conduct disorder	0.021	0.343	CrCbGaD
Droxidopa—Dopamine—COMT—conduct disorder	0.0103	0.167	CrCbGaD
Droxidopa—DDC—Amino acid and derivative metabolism—CGA—conduct disorder	0.00906	0.00973	CbGpPWpGaD
Droxidopa—L-DOPA—DRD4—conduct disorder	0.00894	0.146	CrCbGaD
Droxidopa—ADRA2C—Monoamine GPCRs—DRD4—conduct disorder	0.00886	0.00952	CbGpPWpGaD
Droxidopa—ADRB3—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00885	0.00951	CbGpPWpGaD
Droxidopa—ADRA1D—Amine ligand-binding receptors—DRD4—conduct disorder	0.00883	0.00949	CbGpPWpGaD
Droxidopa—ADRA1B—Monoamine GPCRs—DRD4—conduct disorder	0.00872	0.00937	CbGpPWpGaD
Droxidopa—ADRB1—Melatonin metabolism and effects—MAOA—conduct disorder	0.0085	0.00913	CbGpPWpGaD
Droxidopa—Dopamine—DRD4—conduct disorder	0.00831	0.136	CrCbGaD
Droxidopa—ADRB1—Amine ligand-binding receptors—DRD4—conduct disorder	0.00805	0.00865	CbGpPWpGaD
Droxidopa—ADRA2B—Amine ligand-binding receptors—DRD4—conduct disorder	0.00797	0.00857	CbGpPWpGaD
Droxidopa—ADRB2—Amine ligand-binding receptors—DRD4—conduct disorder	0.00787	0.00846	CbGpPWpGaD
Droxidopa—ADRA1A—Monoamine GPCRs—DRD4—conduct disorder	0.00775	0.00833	CbGpPWpGaD
Droxidopa—Dopamine—MAOA—conduct disorder	0.00774	0.126	CrCbGaD
Droxidopa—ADRA2C—Amine ligand-binding receptors—DRD4—conduct disorder	0.00745	0.00801	CbGpPWpGaD
Droxidopa—ADRA1B—Amine ligand-binding receptors—DRD4—conduct disorder	0.00733	0.00788	CbGpPWpGaD
Droxidopa—PAH—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00728	0.00783	CbGpPWpGaD
Droxidopa—ADRA2A—Monoamine GPCRs—DRD4—conduct disorder	0.0072	0.00774	CbGpPWpGaD
Droxidopa—ADRA1D—Monoamine GPCRs—HTR2A—conduct disorder	0.00686	0.00737	CbGpPWpGaD
Droxidopa—ADRA1A—Amine ligand-binding receptors—DRD4—conduct disorder	0.00651	0.007	CbGpPWpGaD
Droxidopa—DDC—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.00626	0.00673	CbGpPWpGaD
Droxidopa—ADRB1—Monoamine GPCRs—HTR2A—conduct disorder	0.00625	0.00671	CbGpPWpGaD
Droxidopa—ADRA2B—Monoamine GPCRs—HTR2A—conduct disorder	0.00619	0.00665	CbGpPWpGaD
Droxidopa—ADRB2—Monoamine GPCRs—HTR2A—conduct disorder	0.00611	0.00657	CbGpPWpGaD
Droxidopa—ADRA2A—Amine ligand-binding receptors—DRD4—conduct disorder	0.00605	0.0065	CbGpPWpGaD
Droxidopa—PAH—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00594	0.00638	CbGpPWpGaD
Droxidopa—ADRB1—G alpha (s) signalling events—CGA—conduct disorder	0.00593	0.00637	CbGpPWpGaD
Droxidopa—ADRB2—G alpha (s) signalling events—CGA—conduct disorder	0.0058	0.00623	CbGpPWpGaD
Droxidopa—ADRA2C—Monoamine GPCRs—HTR2A—conduct disorder	0.00578	0.00621	CbGpPWpGaD
Droxidopa—ADRA1D—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00576	0.00619	CbGpPWpGaD
Droxidopa—ADRA1B—Monoamine GPCRs—HTR2A—conduct disorder	0.00569	0.00612	CbGpPWpGaD
Droxidopa—ADRB1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00525	0.00564	CbGpPWpGaD
Droxidopa—ADRA2B—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0052	0.00559	CbGpPWpGaD
Droxidopa—ADRB2—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00514	0.00552	CbGpPWpGaD
Droxidopa—DDC—Circadian rythm related genes—SLC6A4—conduct disorder	0.00511	0.00549	CbGpPWpGaD
Droxidopa—ADRA1A—Monoamine GPCRs—HTR2A—conduct disorder	0.00505	0.00543	CbGpPWpGaD
Droxidopa—Dopamine—SLC6A4—conduct disorder	0.00499	0.0814	CrCbGaD
Droxidopa—ADRA2C—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00486	0.00522	CbGpPWpGaD
Droxidopa—DDC—Circadian rythm related genes—DRD4—conduct disorder	0.00481	0.00517	CbGpPWpGaD
Droxidopa—ADRA1B—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00478	0.00514	CbGpPWpGaD
Droxidopa—ADRB3—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00476	0.00512	CbGpPWpGaD
Droxidopa—DDC—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00471	0.00506	CbGpPWpGaD
Droxidopa—ADRA2A—Monoamine GPCRs—HTR2A—conduct disorder	0.0047	0.00505	CbGpPWpGaD
Droxidopa—ADRA1D—GPCRs, Other—DRD4—conduct disorder	0.00467	0.00502	CbGpPWpGaD
Droxidopa—ADRA1A—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00425	0.00457	CbGpPWpGaD
Droxidopa—ADRB2—GPCRs, Other—DRD4—conduct disorder	0.00416	0.00447	CbGpPWpGaD
Droxidopa—ADRA2A—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00395	0.00424	CbGpPWpGaD
Droxidopa—DDC—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00384	0.00413	CbGpPWpGaD
Droxidopa—SLC6A2—NRF2 pathway—SLC6A4—conduct disorder	0.00366	0.00393	CbGpPWpGaD
Droxidopa—ADRB3—GPCR ligand binding—CGA—conduct disorder	0.00363	0.0039	CbGpPWpGaD
Droxidopa—SLC6A2—autonomic nervous system—conduct disorder	0.0035	0.429	CbGeAlD
Droxidopa—PAH—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00315	0.00338	CbGpPWpGaD
Droxidopa—ADRB3—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00311	0.00335	CbGpPWpGaD
Droxidopa—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0031	0.00333	CbGpPWpGaD
Droxidopa—SLC16A10—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.00309	0.00332	CbGpPWpGaD
Droxidopa—ADRA1D—GPCRs, Other—HTR2A—conduct disorder	0.00305	0.00327	CbGpPWpGaD
Droxidopa—ADRB1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00283	0.00304	CbGpPWpGaD
Droxidopa—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0028	0.00301	CbGpPWpGaD
Droxidopa—ADRB2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00277	0.00297	CbGpPWpGaD
Droxidopa—ADRB2—GPCRs, Other—HTR2A—conduct disorder	0.00271	0.00292	CbGpPWpGaD
Droxidopa—ADRB3—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00267	0.00287	CbGpPWpGaD
Droxidopa—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00262	0.00281	CbGpPWpGaD
Droxidopa—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00258	0.00277	CbGpPWpGaD
Droxidopa—PAH—Metabolism—CGA—conduct disorder	0.00257	0.00276	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR ligand binding—CGA—conduct disorder	0.00236	0.00254	CbGpPWpGaD
Droxidopa—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00229	0.00246	CbGpPWpGaD
Droxidopa—ADRB1—GPCR ligand binding—CGA—conduct disorder	0.00215	0.00231	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR ligand binding—CGA—conduct disorder	0.00213	0.00229	CbGpPWpGaD
Droxidopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00213	0.00228	CbGpPWpGaD
Droxidopa—ADRB2—GPCR ligand binding—CGA—conduct disorder	0.00211	0.00226	CbGpPWpGaD
Droxidopa—ADRB3—GPCR downstream signaling—CGA—conduct disorder	0.00205	0.0022	CbGpPWpGaD
Droxidopa—DDC—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00204	0.00219	CbGpPWpGaD
Droxidopa—ADRB3—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00203	0.00218	CbGpPWpGaD
Droxidopa—ADRB3—GPCR ligand binding—DRD4—conduct disorder	0.00203	0.00218	CbGpPWpGaD
Droxidopa—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00203	0.00218	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR ligand binding—CGA—conduct disorder	0.00199	0.00214	CbGpPWpGaD
Droxidopa—ADRA2B—G alpha (i) signalling events—DRD4—conduct disorder	0.00197	0.00212	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR ligand binding—CGA—conduct disorder	0.00196	0.00211	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—CGA—conduct disorder	0.00186	0.002	CbGpPWpGaD
Droxidopa—ADRB1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00185	0.00199	CbGpPWpGaD
Droxidopa—SLC6A2—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.00184	0.00198	CbGpPWpGaD
Droxidopa—ADRA2C—G alpha (i) signalling events—DRD4—conduct disorder	0.00184	0.00198	CbGpPWpGaD
Droxidopa—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00183	0.00197	CbGpPWpGaD
Droxidopa—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00181	0.00194	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR ligand binding—CGA—conduct disorder	0.00174	0.00187	CbGpPWpGaD
Droxidopa—ADRB3—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00174	0.00187	CbGpPWpGaD
Droxidopa—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00174	0.00187	CbGpPWpGaD
Droxidopa—ADRA1D—G alpha (q) signalling events—HTR2A—conduct disorder	0.00171	0.00184	CbGpPWpGaD
Droxidopa—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00171	0.00184	CbGpPWpGaD
Droxidopa—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00168	0.00181	CbGpPWpGaD
Droxidopa—DDC—Metabolism—CGA—conduct disorder	0.00166	0.00179	CbGpPWpGaD
Droxidopa—DDC—Circadian rythm related genes—EP300—conduct disorder	0.00166	0.00179	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR ligand binding—CGA—conduct disorder	0.00162	0.00174	CbGpPWpGaD
Droxidopa—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00158	0.0017	CbGpPWpGaD
Droxidopa—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00157	0.00169	CbGpPWpGaD
Droxidopa—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00155	0.00166	CbGpPWpGaD
Droxidopa—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00153	0.00165	CbGpPWpGaD
Droxidopa—ADRA2A—G alpha (i) signalling events—DRD4—conduct disorder	0.0015	0.00161	CbGpPWpGaD
Droxidopa—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.0015	0.00161	CbGpPWpGaD
Droxidopa—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00147	0.00157	CbGpPWpGaD
Droxidopa—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00144	0.00155	CbGpPWpGaD
Droxidopa—ADRA1B—G alpha (q) signalling events—HTR2A—conduct disorder	0.00142	0.00153	CbGpPWpGaD
Droxidopa—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00139	0.00149	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—CGA—conduct disorder	0.00134	0.00143	CbGpPWpGaD
Droxidopa—ADRB3—GPCR ligand binding—HTR2A—conduct disorder	0.00133	0.00142	CbGpPWpGaD
Droxidopa—ADRA1D—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00132	0.00142	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR ligand binding—DRD4—conduct disorder	0.00132	0.00142	CbGpPWpGaD
Droxidopa—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00128	0.00138	CbGpPWpGaD
Droxidopa—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00127	0.00137	CbGpPWpGaD
Droxidopa—ADRA1A—G alpha (q) signalling events—HTR2A—conduct disorder	0.00126	0.00136	CbGpPWpGaD
Droxidopa—PAH—brain—conduct disorder	0.00125	0.153	CbGeAlD
Droxidopa—ADRB1—GPCR downstream signaling—CGA—conduct disorder	0.00122	0.00131	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—CGA—conduct disorder	0.00121	0.0013	CbGpPWpGaD
Droxidopa—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00121	0.0013	CbGpPWpGaD
Droxidopa—ADRB1—GPCR ligand binding—DRD4—conduct disorder	0.00121	0.0013	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—CGA—conduct disorder	0.00121	0.0013	CbGpPWpGaD
Droxidopa—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00119	0.00128	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR ligand binding—DRD4—conduct disorder	0.00119	0.00128	CbGpPWpGaD
Droxidopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00119	0.00128	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—CGA—conduct disorder	0.00119	0.00128	CbGpPWpGaD
Droxidopa—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00118	0.00127	CbGpPWpGaD
Droxidopa—ADRB2—GPCR ligand binding—DRD4—conduct disorder	0.00118	0.00127	CbGpPWpGaD
Droxidopa—PAH—Metabolism—COMT—conduct disorder	0.00116	0.00125	CbGpPWpGaD
Droxidopa—PAH—Metabolism—MAOA—conduct disorder	0.00115	0.00124	CbGpPWpGaD
Droxidopa—ADRB3—GPCR downstream signaling—DRD4—conduct disorder	0.00115	0.00123	CbGpPWpGaD
Droxidopa—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00113	0.00122	CbGpPWpGaD
Droxidopa—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00113	0.00121	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—CGA—conduct disorder	0.00113	0.00121	CbGpPWpGaD
Droxidopa—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00112	0.0012	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR ligand binding—DRD4—conduct disorder	0.00112	0.0012	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—CGA—conduct disorder	0.00111	0.00119	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—CGA—conduct disorder	0.0011	0.00119	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—CGA—conduct disorder	0.0011	0.00118	CbGpPWpGaD
Droxidopa—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.0011	0.00118	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR ligand binding—DRD4—conduct disorder	0.0011	0.00118	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—CGA—conduct disorder	0.00109	0.00118	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—CGA—conduct disorder	0.00108	0.00116	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—DRD4—conduct disorder	0.00104	0.00112	CbGpPWpGaD
Droxidopa—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00103	0.00111	CbGpPWpGaD
Droxidopa—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00102	0.0011	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—CGA—conduct disorder	0.00102	0.0011	CbGpPWpGaD
Droxidopa—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00101	0.00109	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—CGA—conduct disorder	0.00101	0.00108	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—CGA—conduct disorder	0.000984	0.00106	CbGpPWpGaD
Droxidopa—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000975	0.00105	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR ligand binding—DRD4—conduct disorder	0.000975	0.00105	CbGpPWpGaD
Droxidopa—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000956	0.00103	CbGpPWpGaD
Droxidopa—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000941	0.00101	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—CGA—conduct disorder	0.000915	0.000983	CbGpPWpGaD
Droxidopa—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000906	0.000974	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR ligand binding—DRD4—conduct disorder	0.000906	0.000974	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—CGA—conduct disorder	0.000894	0.000961	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—WASF1—conduct disorder	0.000881	0.000947	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR ligand binding—HTR2A—conduct disorder	0.000863	0.000928	CbGpPWpGaD
Droxidopa—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000836	0.000898	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—CGA—conduct disorder	0.000831	0.000892	CbGpPWpGaD
Droxidopa—ADRB1—GPCR ligand binding—HTR2A—conduct disorder	0.000787	0.000845	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR ligand binding—HTR2A—conduct disorder	0.000779	0.000838	CbGpPWpGaD
Droxidopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000777	0.000834	CbGpPWpGaD
Droxidopa—ADRB2—GPCR ligand binding—HTR2A—conduct disorder	0.000769	0.000827	CbGpPWpGaD
Droxidopa—DDC—Metabolism—COMT—conduct disorder	0.000751	0.000807	CbGpPWpGaD
Droxidopa—ADRB3—GPCR downstream signaling—HTR2A—conduct disorder	0.000749	0.000805	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—DRD4—conduct disorder	0.000748	0.000803	CbGpPWpGaD
Droxidopa—DDC—Metabolism—MAOA—conduct disorder	0.000745	0.000801	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR ligand binding—HTR2A—conduct disorder	0.000728	0.000782	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—CGA—conduct disorder	0.000722	0.000776	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR ligand binding—HTR2A—conduct disorder	0.000716	0.00077	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CGA—conduct disorder	0.000716	0.00077	CbGpPWpGaD
Droxidopa—DDC—brain—conduct disorder	0.000711	0.0871	CbGeAlD
Droxidopa—ADRB1—GPCR downstream signaling—DRD4—conduct disorder	0.000681	0.000732	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—HTR2A—conduct disorder	0.00068	0.000731	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—DRD4—conduct disorder	0.000679	0.00073	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—DRD4—conduct disorder	0.000675	0.000725	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—DRD4—conduct disorder	0.000666	0.000716	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CGA—conduct disorder	0.000653	0.000701	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CGA—conduct disorder	0.000647	0.000695	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CGA—conduct disorder	0.000638	0.000686	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR ligand binding—HTR2A—conduct disorder	0.000636	0.000684	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—DRD4—conduct disorder	0.000631	0.000678	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—DRD4—conduct disorder	0.000621	0.000667	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—DRD4—conduct disorder	0.000619	0.000665	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—DRD4—conduct disorder	0.000616	0.000662	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—DRD4—conduct disorder	0.000613	0.000659	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—DRD4—conduct disorder	0.000605	0.00065	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CGA—conduct disorder	0.000604	0.000649	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CGA—conduct disorder	0.000594	0.000639	CbGpPWpGaD
Droxidopa—PAH—Disease—EP300—conduct disorder	0.000594	0.000638	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR ligand binding—HTR2A—conduct disorder	0.000591	0.000635	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—CGA—conduct disorder	0.000587	0.000631	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—WASF1—conduct disorder	0.000574	0.000617	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—DRD4—conduct disorder	0.000573	0.000615	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—DRD4—conduct disorder	0.000564	0.000606	CbGpPWpGaD
Droxidopa—ADRA1B—brain—conduct disorder	0.000561	0.0687	CbGeAlD
Droxidopa—ADRA1A—GPCR downstream signaling—DRD4—conduct disorder	0.000551	0.000592	CbGpPWpGaD
Droxidopa—ADRA1D—brain—conduct disorder	0.000548	0.0672	CbGeAlD
Droxidopa—ADRA1A—Signaling Pathways—CGA—conduct disorder	0.000528	0.000567	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—WASF1—conduct disorder	0.000523	0.000562	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—WASF1—conduct disorder	0.000518	0.000557	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—DRD4—conduct disorder	0.000512	0.00055	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—WASF1—conduct disorder	0.000512	0.00055	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—DRD4—conduct disorder	0.000501	0.000538	CbGpPWpGaD
Droxidopa—PAH—Metabolism—EP300—conduct disorder	0.000498	0.000535	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CGA—conduct disorder	0.000491	0.000527	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—HTR2A—conduct disorder	0.000488	0.000524	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—WASF1—conduct disorder	0.000484	0.00052	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—WASF1—conduct disorder	0.000476	0.000512	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—DRD4—conduct disorder	0.000465	0.0005	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—HTR2A—conduct disorder	0.000445	0.000478	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—HTR2A—conduct disorder	0.000443	0.000476	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—HTR2A—conduct disorder	0.00044	0.000473	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—HTR2A—conduct disorder	0.000435	0.000467	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—WASF1—conduct disorder	0.000423	0.000455	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—HTR2A—conduct disorder	0.000411	0.000442	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—HTR2A—conduct disorder	0.000405	0.000435	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—HTR2A—conduct disorder	0.000404	0.000434	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—HTR2A—conduct disorder	0.000402	0.000432	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—DRD4—conduct disorder	0.000401	0.000431	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—HTR2A—conduct disorder	0.0004	0.00043	CbGpPWpGaD
Droxidopa—ADRB1—brain—conduct disorder	0.000398	0.0488	CbGeAlD
Droxidopa—ADRB2—Signaling by GPCR—HTR2A—conduct disorder	0.000395	0.000424	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—WASF1—conduct disorder	0.000393	0.000423	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—HTR2A—conduct disorder	0.000374	0.000401	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—EP300—conduct disorder	0.000369	0.000397	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—HTR2A—conduct disorder	0.000368	0.000395	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—DRD4—conduct disorder	0.000365	0.000393	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—DRD4—conduct disorder	0.000362	0.000389	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—HTR2A—conduct disorder	0.00036	0.000386	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—DRD4—conduct disorder	0.000358	0.000384	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—EP300—conduct disorder	0.000345	0.000371	CbGpPWpGaD
Droxidopa—SLC6A2—brain—conduct disorder	0.000339	0.0415	CbGeAlD
Droxidopa—ADRA2C—Signaling Pathways—DRD4—conduct disorder	0.000338	0.000363	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—HTR2A—conduct disorder	0.000334	0.000359	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—DRD4—conduct disorder	0.000333	0.000358	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—HTR2A—conduct disorder	0.000327	0.000351	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—COMT—conduct disorder	0.000326	0.00035	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—MAOA—conduct disorder	0.000324	0.000348	CbGpPWpGaD
Droxidopa—DDC—Metabolism—EP300—conduct disorder	0.000322	0.000346	CbGpPWpGaD
Droxidopa—ADRA1A—brain—conduct disorder	0.000315	0.0386	CbGeAlD
Droxidopa—ADRA2A—Signaling by GPCR—HTR2A—conduct disorder	0.000303	0.000326	CbGpPWpGaD
Droxidopa—ADRA2C—brain—conduct disorder	0.0003	0.0368	CbGeAlD
Droxidopa—ADRA1A—Signaling Pathways—DRD4—conduct disorder	0.000296	0.000318	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—EP300—conduct disorder	0.00028	0.000301	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—DRD4—conduct disorder	0.000275	0.000295	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—COMT—conduct disorder	0.000265	0.000285	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—MAOA—conduct disorder	0.000263	0.000283	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—HTR2A—conduct disorder	0.000262	0.000281	CbGpPWpGaD
Droxidopa—ADRA2A—brain—conduct disorder	0.000239	0.0293	CbGeAlD
Droxidopa—ADRB1—Signaling Pathways—HTR2A—conduct disorder	0.000238	0.000256	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—HTR2A—conduct disorder	0.000236	0.000254	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—HTR2A—conduct disorder	0.000233	0.000251	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—HTR2A—conduct disorder	0.000221	0.000237	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—HTR2A—conduct disorder	0.000217	0.000233	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—EP300—conduct disorder	0.000213	0.000229	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—HTR2A—conduct disorder	0.000193	0.000207	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—HTR2A—conduct disorder	0.000179	0.000193	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—EP300—conduct disorder	0.00014	0.00015	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—EP300—conduct disorder	0.000139	0.000149	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—EP300—conduct disorder	0.000126	0.000136	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—EP300—conduct disorder	0.000125	0.000135	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—EP300—conduct disorder	0.000124	0.000133	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—EP300—conduct disorder	0.000117	0.000126	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—EP300—conduct disorder	0.000115	0.000124	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—EP300—conduct disorder	0.000114	0.000122	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—EP300—conduct disorder	0.000102	0.00011	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—EP300—conduct disorder	9.5e-05	0.000102	CbGpPWpGaD
